Physician profile
Christopher Kopp
NPI 1679568596
$786.06
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $240 · 2021: $57.42.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $116.79 | 2019-2021 | |
| 180 Medical, INC. | $103.05 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $102.38 | 2019-2020 | |
| Astellas Pharma US INC | $80.14 | 2019-2020 | |
| Pfizer INC. | $68.83 | 2019-2020 | |
| Neotract INC. | $41.87 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.78 | 2019 | |
| Merck Sharp & Dohme LLC | $38.59 | 2020 | |
| Abbvie INC. | $31.68 | 2019-2020 | |
| Coloplast Corp | $26.69 | 2019-2020 | |
| Blue Earth Diagnostics | $24.66 | 2019 | |
| Allergan, INC. | $22.63 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $21.27 | 2019 | |
| Travere Therapeutics, INC. | $20.89 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.26 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $13.68 | 2019 | |
| Mission Pharmacal Company | $12.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.